Plain-English translation of NCT04833140 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether estradiol—a form of estrogen delivered through a skin patch—can help treat nonalcoholic steatohepatitis (NASH), a serious liver condition where fat builds up and causes inflammation and scarring. The study focuses on postmenopausal women, who have low estrogen levels and are at higher risk for this disease. Women with an intact uterus will also receive progesterone to protect their uterine health.
NASH is becoming more common, but there are very few approved treatments. Early research suggests that low estrogen after menopause may play a role in developing this disease, so testing this medication could offer a new treatment option for postmenopausal women.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to either receive an or a placebo patch that you wear daily on your skin. If you have a uterus, you will also receive either a progesterone vaginal tablet or placebo tablet to insert daily. The study involves regular clinic visits where your liver health will be monitored through blood tests and possibly imaging to see if the medication is helping reduce liver fat and scarring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States